The company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19.
Intrasense™ announces its 2019 annual results.
Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.
All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.
This new version of Myrian® brings many clinical innovations and a new application.
Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.
Myrian® XP-Mammo, can now be commercialized on the European market.
Myrian® XP Prostate, the new reference tool for worldwide prostate experts.
Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.
Presentation of 3 innovative products based on Myrian® technology.
Select your choice...Receive newsGet in touch with the investor serviceOther
By ticking this box, I agree to my data being used by Intrasense to respond to my request and to receive appropriate communications or information. I may withdraw my consent at any time by writing to the Data Protection Officer at dpo@intrasense.fr. For further information, please consult our Privacy Policy.
Please leave this field empty.
En cochant cette case, j'accepte que mes données soient utilisées par Intrasense pour répondre à ma demande et recevoir des communications ou des informations appropriées. Je peux retirer mon consentement à tout moment en écrivant au Délégué à la protection des données à dpo@intrasense.fr. Pour en savoir plus, consultez notre Politique de Confidentialité.
